A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Inclusion Criteria: * Have a diagnosis of adult onset rheumatoid arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria * Have moderately-to-severely active RA, at screening and baseline, defined by the presence of * ≥6 swollen joints based on 66 joint count, and * ≥6 tender joints based on 68 joint count. * Have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic DMARD (csDMARD), biologic DMARD ( bDMARD), or targeted synthetic DMARD (tsDMARD) treatment. Exclusion Criteria: * Have Class IV RA according to ACR revised criteria. * Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to * poorly controlled diabetes or hypertension * chronic kidney disease stage IIIb, IV, or V * symptomatic heart failure according to New York Heart Association Class II, III, or IV * myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack, within the past 12 months before randomization * severe chronic pulmonary disease, for example, requiring oxygen therapy * major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to, * systemic lupus erythematosus * psoriatic arthritis * axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis …